Immune-enhanced fusion protein for expressing TGF [beta] RII and TIM3 extracellular regions and application thereof

The invention discloses a fusion protein capable of simultaneously intervening in TGF beta RII and TIM3 mediated signaling pathways, namely, TGF beta RII and TIM3 extracellular regions are expressed on a cell therapy product, so that the inhibition effect of a tumor microenvironment is relieved, the immunocompetence is maintained, and a foundation is laid for immunotherapy of advanced tumors..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 12. Sept. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

XU ZHENYU [VerfasserIn]
TANG LEI [VerfasserIn]
HUANG HOUBAO [VerfasserIn]
ZHENG HAN [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
bio
C07K: Peptides (peptides containing β-lactam rings c07d; (...)
C12N: Microorganisms or enzymes; compositions thereof; pr (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-09-12, Last update posted on www.tib.eu: 2023-12-19, Last updated: 2023-12-22

Patentnummer:

CN116731205

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA018694896